NewPace is finalizing a subcutaneous implantable cardioverter defibrillator (ICD) that is designed to be a life-saving device in the event of sudden cardiac arrest.
The NewPace defibrillator differs from standard ICDs in that it does not have leads in the heart. The rechargeable device is implanted subcutaneously with no need for fluoroscopy, and communicates by Bluetooth with a smartphone. The string-shaped defibrillator requires one hour per year for wireless recharge, and communicates at low energy with smartphones for monitoring. The subcutaneous implantation requires no in-patient care.